Press "Enter" to skip to content

NMPA Accepts New Drug Application for IBI301, a Biosimilar Product Candidate of Rituximab (MabThera/Rituxan) – Finger Lakes Times

admin 0

NMPA Accepts New Drug Application for IBI301, a Biosimilar Product Candidate of Rituximab (MabThera/Rituxan)  Finger Lakes Times

SUZHOU, China, June 27, 2019 /PRNewswire/ — Innovent Biologics, Inc. (Innovent) (HKEX: 01801) and Eli Lilly and Company (“Lilly”) jointly announced today …

“lymphoma cancer” – Google News

(Visited 2 times, 1 visits today)

Leave a Reply

Your email address will not be published. Required fields are marked *